Q-omics provides the consensus-scored ZNF302 profile across patient tissues and cancer cell-line models. ZNF302 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, ZNF302 is differentially expressed in 9, with the highest sampling consensus in KICH. Additionally, ZNF302 RNA expression shows 20,823 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UCS, KICH, and THYM as cancer lineages where ZNF302 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF302 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF302 survival associations across molecular data types. ZNF302 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (4) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF302 RNA expression–survival associations across cancer types. High ZNF302 expression shows unfavorable associations in UCEC and LGG, but favorable associations in UCS, HNSC, BRCA and READ. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCS as the clearest survival context for ZNF302 RNA expression.
This table summarizes ZNF302 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 2. The strongest signals are observed in THCA for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for ZNF302. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF302 shows lower tumor expression in KICH, THCA and UCEC and higher tumor expression in LIHC, CHOL and KIRC. The KICH box plot shows higher ZNF302 RNA expression in normal versus tumor tissue (log2 FC = −0.949, t-test p < 0.001).
This table shows molecular features associated with ZNF302 in patient tissues and cancer cell lines. In patient samples, ZNF302 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF302 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in SKIN and UPPER_AERODIGESTIVE_TRACT.
